youtube.com/watch?v=GW3UXHq...
Participants include Michael Hoffman, Michael Morris, Oliver Sartor and Alicia Morgans. Discusses recent TheraP and VISION trial results; who may benefit; side effects; survival benefits; future outlook.
youtube.com/watch?v=GW3UXHq...
Participants include Michael Hoffman, Michael Morris, Oliver Sartor and Alicia Morgans. Discusses recent TheraP and VISION trial results; who may benefit; side effects; survival benefits; future outlook.
Thank you for posting this link as I couldn't attend at the last minute. Many of the participants are leading researchers and this webinar is an open conversation on the ins, outs and roundabouts of Lu177 and related studies.For anyone considering Lu177 you should watch this at least twice as potential patients are not the target audience, it is information dense and jumps quickly between key topics.
Thanks for posting. Lupron and Zytiga no longer effective. Waiting for a call back from Dana Farber for test study. Many questions. How this impacts future studies down the road? Is it a blind study?